The never-ending explosion in the cost of new oncology drugs is reducing in many countries the access to the most recent, effective anticancer therapies and represents a significant obstacle to the design and realization of combinatorial trials. Already approved, anticancer and nonanticancer drugs can be considered for in silico, preclinical, and clinical repurposing approaches and offer the significant advantages of a potentially cheaper, faster, and safer validation. This review discusses recent advances and challenges in the field.
From the *Laboratory of Hematology-Oncology and
†Department of Experimental Oncology, IRCCS European Institute of Oncology, Milan, Italy.
S.O. and S. Roma contributed equally to this work.
Conflicts of Interest and Source of Funding: The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article. Funded in part by AIRC.
Reprints: Francesco Bertolini, MD, PhD, Laboratory of Hematology-Oncology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy. E-mail: firstname.lastname@example.org.